Evaluation of the efficacy of ginger in reduction chemotherapy-induced nausea and vomiting in newly diagnosed breast cancer patients receiving doxorubicin(adriamycin)-based chemotherapy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050517581N1

Enrollment

110

Registered

2015-02-13

Start date

2014-08-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Breast, unspecified

Interventions

Intervention 1: Intervention group: all patients with new breast cancer that assigned to this group randomly, should have Complete Blood Count before any cycle of chemotherapy and all of them receive

Treatment - Drugs

Intervention group: all patients with new breast cancer that assigned to this group randomly, should have Complete Blood Count before any cycle of chemotherapy and all of them receive standard anti-e

Control group: all patients with new breast cancer that assigned to this group randomly, should have Complete Blood Cell before any cycle of chemotherapy and all of them receive standard anti-emetic t

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: New diagnosed breast cancer ;All ages ;Female ;No previous chemotherapy ;Prescription of doxorubicin-based chemotherapy ;No gastrointestinal obstruction ;No coagulopathy ;Receiving of standard anti-emetic treatment ;Completion of ethic form ;No concurrent hormontherapy or radiotherapy. Exclusion criteria: Bleeding ;Development of gastrointestinal obstruction ;Uncompleted questionnaires ;Less than 3 cycle doxorubicin-based chemotherapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea severity and duration. Timepoint: 3-days. Method of measurement: questionnaire.;Vomiting frequency and duration. Timepoint: 3-days. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Coagulation disorders. Timepoint: 3-weeks. Method of measurement: questionnaire.;Gastrointestinal disorders. Timepoint: 3-weeks. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Pejman Porouhan

Shiraz University of Medical Sciences

porouhan@sums.ac.ir+98 71 3612 5367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026